The molecular targets and clinical trials of CRC include targeting the EGF/EGFR, VEGF-VEGF Receptor (VEGFR), MAPK-RAS/FAR/MEK/ERK and PI3K-mTOR pathways via the usage of anti-EGFR and anti-angiogenic monoclonal antibodies, tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICI) [11,12,13,14]. Here, EGFR is linked to colorectal carcinoma.